Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience

Table 1 Baseline demographics

Baseline demographics	Total population (n = 92)	Treatment naïve (n = 55)	Treatment experienced, viraemic (n = 20)	Treatment experienced, non-viraemic (n = 17)
Age (yr)
Mean (IQR)	46 (36-54)	42 (32-53)	48 (41-57)	55 (44-60)
Gender n (%)
Male	64 (69.6)	39 (70.9)	11 (55)	14 (82.4)
Female	28 (30.4)	16 (29.1)	9 (45)	3 (17.6)
Ethnic origin n (%)
African	4 (4.3)	3 (5.5)	0	1 (5.9)
Asian	77 (83.7)	48 (87.3)	16 (80)	13 (76.5)
Caucasian	5 (5.4)	3 (5.5)	0	2 (11.8)
Mediterranean	2 (2.2)	1 (1.8)	1 (5)	0
Middle Eastern	1 (1.1)	0	1 (5)	0
Duration of therapy (mo)
Median (IQR)	24 (6-42)	24 (12-36)	24 (6-54)	24 (12-42)
HBe antigen status n (%)
HBeAg positive	30 (32.6)	19 (34.5)	10 (50)	1 (5.9)
HBeAg negative	62 (67.4)	36 (65.5)	10 (50)	16 (94.1)
Treatment history n (%)
Experienced	37 (40.2)	0	20 (100)	17 (100)
Adefovir	10 (27)		4 (20)	6 (35.3)
Adefovir/lamivudine	13 (35.1)		6 (30)	7 (41.2)
Lamivudine	6 (16.2)		4 (20)	2 (11.8)
Lamivudine/entecavir	1 (2.7)		1 (5)	0
Entecavir	5 (13.5)		4 (20)	1 (5.9)
Entecavir/adefovir	2 (5.4)		1 (5)	1 (5.9)
Naïve	55 (59.8)	55 (100)	0	0
HBV DNA load (IU/mL) n (%)
< 20	17	-	-	17 (100)
20-2000	29 (31.5)	6 (10.9)	6 (30)	0
2000-100000	11 (12)	8 (14.5)	3 (15)	0
> 100000	52 (56.5)	41 (74.5)	11 (55)	0
Median (IQR)	1.8 × 105 (302-1.6 × 107)	9.4 × 105 (9.7 × 104-3.7 × 107)	1.8 × 105 (790-4.1 × 106)	N/A
ALT (U/L) n (%)
0-20	11 (12)	2 (3.6)	4 (20)	5 (29.4)
20-40	26 (28.3)	10 (18.2)	8 (40)	8 (47.1)
40-400	51 (55.4)	39 (70.9)	8 (40)	4 (23.5)
> 400	4 (4.3)	4 (7.3)	0	0
Median (IQR)	30 (22-41.8)	73 (41-140)	34 (22.3-62.3)	24 (19-44)
Serum creatinine (IU/mL)
Median (IQR)	70 (60-81.5)	66.5 (50.8-71.5)	71 (63.5-84.5)	83 (69-93)
Pre-treatment biopsy n (%)	69 (75)	40 (72.7)	16 (80)	14 (82.4)
Fibrosis score n (%)
0	9 (9.8)	5 (9.1)	3 (15)	3 (17.6)
1	31 (33.7)	21 (38.2)	6 (30)	4 (23.5)
2	13 (14.1)	8 (14.5)	3 (15)	2 (11.8)
3	7 (7.6)	1 (1.8)	2 (10)	4 (23.5)
4	9 (9.8)	5 (9.1)	2 (10)	2 (11.8)
Genotype n (%)	35 (38)	6 (10.9)	9 (45)	12 (70.6)
A	3 (3.3)	2 (3.6)	0	1 (5.9)
B	7 (7.6)	2 (3.6)	1 (5)	4 (23.5)
C	13 (14.1)	2 (3.6)	7 (35)	4 (23.5)
D	3 (3.3)	0	0	2 (11.8)

“Treatment experience” refers to previous NA therapy. “Viraemia” refers to HBV DNA > 20 IU/mL. Liver biopsy was scored using the METAVIR scoring system. HBe: Hepatitis B “e”; HBV DNA: Hepatitis B viral deoxyribonucleic acid; ALT: Alanine aminotransferase; N/A: Not applicable.